GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Interpace Biosciences Inc (STU:PF42) » Definitions » Debt-to-Asset

Interpace Biosciences (STU:PF42) Debt-to-Asset : 0.87 (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Interpace Biosciences Debt-to-Asset?

Interpace Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €7.24 Mil. Interpace Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €2.49 Mil. Interpace Biosciences's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was €11.17 Mil. Interpace Biosciences's debt to asset for the quarter that ended in Mar. 2024 was 0.87.


Interpace Biosciences Debt-to-Asset Historical Data

The historical data trend for Interpace Biosciences's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Interpace Biosciences Debt-to-Asset Chart

Interpace Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.14 0.10 0.28 1.01 0.86

Interpace Biosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.98 0.93 0.95 0.86 0.87

Competitive Comparison of Interpace Biosciences's Debt-to-Asset

For the Diagnostics & Research subindustry, Interpace Biosciences's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Interpace Biosciences's Debt-to-Asset Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Interpace Biosciences's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Interpace Biosciences's Debt-to-Asset falls into.



Interpace Biosciences Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Interpace Biosciences's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Interpace Biosciences's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Interpace Biosciences  (STU:PF42) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Interpace Biosciences Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Interpace Biosciences's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Interpace Biosciences (STU:PF42) Business Description

Traded in Other Exchanges
Address
300 Interpace Parkway, Morris Corporate Center 1, Building C, Parsippany, NJ, USA, 07054
Interpace Biosciences Inc is engaged in the life sciences industry. It provides molecular diagnostics, bioinformatics, and pathology services for the evaluation of the risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. The company develops and commercializes genomic tests and related first-line assays principally focused on the early detection of patients with indeterminate biopsies and at high risk of cancer using the latest technology. It operates under one segment which is the business of developing and selling diagnostic clinical services.

Interpace Biosciences (STU:PF42) Headlines

No Headlines